Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.36 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | BCL6 | P41182 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1442996 | 0.93 | ALDH1A1 (0.41) | AAK1SMN1; SMN2KDM4EALDH1A1PDGFRB | |
| SCHEMBL4071074 | 0.77 | KMT2A (0.37) | KMT2AAXL | |
| SCHEMBL31214287 | 0.71 | ALDH1A1 (0.47) | SMN1; SMN2KDM4EALDH1A1KMT2APDGFRB | |
| SCHEMBL5149760 | 0.70 | ABL1 (0.33) | — | |
| SCHEMBL27196854 | 0.70 | KMT2A (0.60) | SMN1; SMN2KDM4EALDH1A1KMT2APDGFRB | |
| SCHEMBL25283172 | 0.66 | ALDH1A1 (0.46) | SMN1; SMN2KDM4EALDH1A1KMT2APDGFRB | |
| SCHEMBL3145566 | 0.66 | KMT2A (0.51) | SMN1; SMN2KDM4EALDH1A1KMT2APDGFRB | |
| SCHEMBL14488164 | 0.66 | EPHX1 (0.36) | SMN1; SMN2KDM4EALDH1A1KMT2A | |
| SCHEMBL1443653 | 0.66 | TRPM8 (0.52) | SMN1; SMN2KDM4EALDH1A1KMT2APDGFRB | |
| SCHEMBL1442896 | 0.66 | PDGFRB (0.39) | SMN1; SMN2KDM4EALDH1A1PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473486-B2 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| EP-2473486-B1 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-09 | — | — | US | disclosed |
| EP-2473486-A1 | NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011026835-A1 | NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | HAMP, DHPS, SLC40A1 | AAK1 1361/4885SMN1; SMN2 4562/4885KDM4E 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.